Towards a future where Alzheimer’s disease pathology is stopped before the onset of dementia

Nature Aging, Journal Year: 2023, Volume and Issue: 3(5), P. 494 - 505

Published: May 18, 2023

Language: Английский

---

Increasing participant diversity in AD research: Plans for digital screening, blood testing, and a community‐engaged approach in the Alzheimer's Disease Neuroimaging Initiative 4

Alzheimer s & Dementia, Journal Year: 2022, Volume and Issue: 19(1), P. 307 - 317

Published: Oct. 9, 2022

Abstract Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to validate biomarkers for disease (AD) clinical trials. To improve generalizability, ADNI4 enroll 50‐60% of its new participants from underrepresented populations (URPs) using biofluid and digital technologies. has received funding the National Institute on Aging beginning September 2022. Methods will recruit URPs community‐engaged approaches. An online portal screen 20,000 participants, 4000 whom (50‐60% URPs) be tested plasma APOE . From this, 500 undergo in‐clinic assessment joining ADNI3 rollover participants. Remaining (∼3500) longitudinal cognitive testing. add MRI sequences PET tracers. Project 1 optimize in AD Results Discussion generalizability results, use remote blood screening, continue providing clinical, biomarker, autopsy data investigators.

Language: Английский

---

A global view of the genetic basis of Alzheimer disease

Nature Reviews Neurology, Journal Year: 2023, Volume and Issue: 19(5), P. 261 - 277

Published: April 6, 2023

Language: Английский

---

Artificial intelligence for biomarker discovery in Alzheimer's disease and dementia

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 19(12), P. 5860 - 5871

Published: Aug. 31, 2023

Abstract With the increase in large multimodal cohorts and high‐throughput technologies, potential for discovering novel biomarkers is no longer limited by data set size. Artificial intelligence (AI) machine learning approaches have been developed to detect interactions complex sets. We discuss exemplar uses evaluate current applications limitations of AI discover biomarkers. Remaining challenges include a lack diversity sets available, sheer complexity investigating interactions, invasiveness cost some biomarkers, poor reporting studies. Overcoming these will involve collecting from underrepresented populations, developing more powerful approaches, validating use noninvasive adhering guidelines. By harnessing rich through international collaborative innovation, we are well positioned identify clinically useful that accurate, generalizable, unbiased, acceptable clinical practice. Highlights may accelerate dementia biomarker discovery. suitability due size bias cohort selection. Multimodal data, diverse sets, improved real‐world validation, interdisciplinary collaboration required.

Language: Английский

---

Head‐to‐head comparison of leading blood tests for Alzheimer's disease pathology

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(11), P. 8074 - 8096

Published: Oct. 12, 2024

Abstract INTRODUCTION Blood tests have the potential to improve accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access AD‐specific treatments. This study compared leading commercial blood for amyloid pathology and other AD‐related outcomes. METHODS Plasma samples from Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical thickness, dementia severity. Logistic regression models assessed classification accuracies individual or combined plasma biomarkers binarized outcomes, Spearman correlations evaluated continuous relationships between RESULTS Measures p‐tau217, either individually in combination biomarkers, had strongest all DISCUSSION identified biomarker analytes assays that most accurately classified Highlights p‐tau217 status. Aβ42/Aβ40 relatively low higher thickness than NfL. Correlations symptoms low.

Language: Английский

---

Prediction of Alzheimer's disease progression within 6 years using speech: A novel approach leveraging language models

Alzheimer s & Dementia, Journal Year: 2024, Volume and Issue: 20(8), P. 5262 - 5270

Published: June 25, 2024

Abstract INTRODUCTION Identification of individuals with mild cognitive impairment (MCI) who are at risk developing Alzheimer's disease (AD) is crucial for early intervention and selection clinical trials. METHODS We applied natural language processing techniques along machine learning methods to develop a method automated prediction progression AD within 6 years using speech. The study design was evaluated on the neuropsychological test interviews n = 166 participants from Framingham Heart Study, comprising 90 progressive MCI 76 stable cases. RESULTS Our best models, which used features generated speech data, as well age, sex, education level, achieved an accuracy 78.5% sensitivity 81.1% predict MCI‐to‐AD years. DISCUSSION proposed offers fully procedure, providing opportunity inexpensive, broadly accessible, easy‐to‐administer screening tool prediction, facilitating development remote assessment. Highlights Voice recordings exams coupled basic demographics can lead strong predictive models dementia impairment. leveraged AI recognition processed resulting text models. developed AI‐powered pipeline assessment that could enable cost‐effective prognosis Alzehimer's disease.

Language: Английский

---

Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Alzheimer s & Dementia, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 8, 2025

Abstract INTRODUCTION The Alzheimer's Association and the Society of Nuclear Medicine Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) develop AUC tau PET. METHODS identified key research questions that guided systematic literature review on clinical amyloid/tau Building this review, developed 17 scenarios in which or PET may be considered. A modified Delphi approach was used rate each scenario by consensus as “rarely appropriate,” “uncertain,” “appropriate.” Ratings were performed separately stand‐alone modalities. RESULTS For PET, seven rated appropriate, two uncertain, eight rarely appropriate. five six DISCUSSION provide expert recommendations these technologies evolving landscape diagnostics therapeutics disease. Highlights updated goal is assist clinicians identifying useful guiding diagnosis management patients who have, are at risk for, cognitive decline These intended dementia specialists spend significant proportion their effort caring with complaints, well serve general reference broader audience interested implementation practice.

Language: Английский

---

Updated Appropriate Use Criteria for Amyloid and Tau PET: A Report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Journal of Nuclear Medicine, Journal Year: 2025, Volume and Issue: unknown, P. jnumed.124.268756 - jnumed.124.268756

Published: Jan. 8, 2025

The Alzheimer's Association and the Society of Nuclear Medicine Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) develop AUC tau PET. Methods: identified key research questions that guided systematic literature review on clinical amyloid/tau Building this review, developed 17 scenarios in which or PET may be considered. A modified Delphi approach was used rate each scenario by consensus as "rarely appropriate," "uncertain," "appropriate." Ratings were performed separately stand-alone modalities. Results: For PET, 7 rated appropriate, 2 uncertain, 8 rarely appropriate. 5 6 Conclusion: provide expert recommendations these technologies evolving landscape diagnostics therapeutics disease.

Language: Английский

---

The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022

Alzheimer s & Dementia, Journal Year: 2023, Volume and Issue: 20(1), P. 652 - 694

Published: Sept. 12, 2023

The Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, biofluid samples. We used conventional search methods identify 1459 publications from 2021 2022 using data/samples reviewed 291 impactful studies. This review details how studies improved progression understanding trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, modeling trials plasma biomarkers like phosphorylated tau showed promise for use. Biomarkers amyloid beta, tau, neurodegeneration, inflammation, others were prognostic with individualized prediction algorithms available online. Studies supported the cascade, emphasized importance neuroinflammation, detailed widespread heterogeneity disease, linked genetic vascular risk, co-pathologies, sex, resilience. Biological subtypes consistently observed. Generalizability results is limited by lack cohort diversity, an issue ADNI-4 address enrolling a diverse cohort.

Language: Английский

---

Quantification of race/ethnicity representation in Alzheimer’s disease neuroimaging research in the USA: a systematic review

Communications Medicine, Journal Year: 2023, Volume and Issue: 3(1)

Published: July 25, 2023

Abstract Background Racial and ethnic minoritized groups are disproportionately at risk for Alzheimer’s Disease (AD), but not sufficiently recruited in AD neuroimaging research the United States. This is important as sample composition impacts generalizability of findings, biomarker cutoffs, treatment effects. No studies have quantified breadth race/ethnicity representation literature. Methods review identified median US-based samples available free full-text articles on PubMed. Two types published were analyzed: that directly report data (i.e., direct studies), do used from a cohort study/database does this information indirect studies). Results Direct ( n = 719) 88.9% white or 87.4% Non-Hispanic white, 7.3% Black/African American, 3.4% Hispanic/Latino ethnicity, with 0% Asian Native Hawaiian/Pacific Islander, American Indian/Alaska Native, Multiracial, Other Race participants. Cohort studies/databases 44) which 1745) derived more diverse, 84.2% 83.7% 11.6% 4.7% Hispanic/Latino, 1.75% Notably, 94% derive just 10 studies/databases. Comparisons two time periods using split publication year, 1994–2017 2018–2022, indicate diversity has improved recently, particularly participants (3.39% 8.29% 2018-2022). Conclusions There still underrepresentation all relative to Census data, especially individuals. The literature will benefit increased representative recruitment ethnic/racial minorities. More transparent reporting needed.

Language: Английский

---